PRETREATMENT OF DONOR MICE WITH GRANULOCYTE-COLONY-STIMULATING FACTORPOLARIZES DONOR T-LYMPHOCYTES TOWARD TYPE-2 CYTOKINE PRODUCTION AND REDUCES SEVERITY OF EXPERIMENTAL GRAFT-VERSUS-HOST DISEASE
Ly. Pan et al., PRETREATMENT OF DONOR MICE WITH GRANULOCYTE-COLONY-STIMULATING FACTORPOLARIZES DONOR T-LYMPHOCYTES TOWARD TYPE-2 CYTOKINE PRODUCTION AND REDUCES SEVERITY OF EXPERIMENTAL GRAFT-VERSUS-HOST DISEASE, Blood, 86(12), 1995, pp. 4422-4429
The incidence and severity of acute graft-versus-host disease (GVHD) a
fter allogeneic transplantation using peripheral blood progenitor cell
s mobilized by granulocyte colony-stimulating factor IG-CSF) appear to
be no worse than those after bone marrow transplantation, despite the
presence of large numbers of T cells in the donor infusion. Experimen
tal studies have shown that type-1 T cells (secreting interleukin-2 [I
L-2] and interferon-gamma) mediate acute GVHD, whereas type-2 T cells
(secreting IL-4 and IL-10) can prevent acute GVHD. We tested the hypot
hesis that G-CSF modulates T-cell function toward a type-2 response an
d thus reduces the severity of acute GVHD. B6 mice were injected with
G-CSF or diluent for 4 days, and their splenic T cells were stimulated
in vitro with alloantigen or mitogen in the absence of G-CSF. T cells
from G-CSF-treated mice showed a significant increase in IL-4 product
ion, with a simultaneous decrease in IL-2 and interferon-gamma product
ion in response to both stimuli. We also examined the effect of G-CSF
pretreatment of donors in a GVHD model (B6 --> B6D2F1). Survival was s
ignificantly improved in recipients of G-CSF-treated donors. Concanava
lin-A-induced cytokine production at day 13 after transplantation also
showed an increase in IL-4 along with a decrease in IL-2 and IFN-gamm
a production by splenocytes from recipients of G-CSF-treated bone marr
ow and T cells. These data show that pretreatment of donors with G-CSF
polarizes donor T cells toward the production of type-2 cytokines, wh
ich is associated with reduced type-1 cytokine production and reduced
severity of acute GVHD. (C) 1996 by The American Society of Hematology
.